Véronique Quillien

3.8k total citations
71 papers, 2.2k citations indexed

About

Véronique Quillien is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Véronique Quillien has authored 71 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 28 papers in Genetics and 21 papers in Oncology. Recurrent topics in Véronique Quillien's work include Glioma Diagnosis and Treatment (26 papers), Immunotherapy and Immune Responses (13 papers) and Cancer Genomics and Diagnostics (10 papers). Véronique Quillien is often cited by papers focused on Glioma Diagnosis and Treatment (26 papers), Immunotherapy and Immune Responses (13 papers) and Cancer Genomics and Diagnostics (10 papers). Véronique Quillien collaborates with scholars based in France, United States and Switzerland. Véronique Quillien's co-authors include Tony Avril, Jean Mosser, Stéphan Saïkali, Abderrahmane Hamlat, Élodie Vauléon, Amandine Etcheverry, Marie de Tayrac, Marc Aubry, Brigitte Collet and Philippe Meneï and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Véronique Quillien

69 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Véronique Quillien France 27 1.0k 893 665 609 562 71 2.2k
Deric M. Park United States 26 861 0.8× 568 0.6× 543 0.8× 311 0.5× 490 0.9× 54 2.1k
Yu Yao China 33 1.1k 1.0× 1.1k 1.3× 893 1.3× 670 1.1× 772 1.4× 112 3.0k
Karim Y. Helmy United States 18 848 0.8× 727 0.8× 407 0.6× 859 1.4× 464 0.8× 20 2.2k
Ken Aldape United States 15 1.3k 1.2× 1.1k 1.3× 540 0.8× 252 0.4× 743 1.3× 21 2.4k
Gouri J. Nanjangud United States 22 986 0.9× 674 0.8× 743 1.1× 424 0.7× 365 0.6× 48 2.2k
Martha Chekenya Norway 25 755 0.7× 578 0.6× 763 1.1× 739 1.2× 378 0.7× 41 2.1k
Serena Pellegatta Italy 27 986 0.9× 738 0.8× 1.0k 1.5× 748 1.2× 513 0.9× 69 2.3k
Chunhui Di United States 18 1.2k 1.1× 510 0.6× 440 0.7× 267 0.4× 353 0.6× 26 2.0k
Olga A. Guryanova United States 17 2.0k 1.9× 1.1k 1.3× 645 1.0× 281 0.5× 1.1k 1.9× 36 3.0k
Alexander Schulte Germany 24 755 0.7× 503 0.6× 951 1.4× 689 1.1× 505 0.9× 36 2.2k

Countries citing papers authored by Véronique Quillien

Since Specialization
Citations

This map shows the geographic impact of Véronique Quillien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Véronique Quillien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Véronique Quillien more than expected).

Fields of papers citing papers by Véronique Quillien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Véronique Quillien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Véronique Quillien. The network helps show where Véronique Quillien may publish in the future.

Co-authorship network of co-authors of Véronique Quillien

This figure shows the co-authorship network connecting the top 25 collaborators of Véronique Quillien. A scholar is included among the top collaborators of Véronique Quillien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Véronique Quillien. Véronique Quillien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quillien, Véronique, Florence Godey, Fanny Le Du, et al.. (2024). Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer. Molecular Oncology. 18(11). 2714–2729. 5 indexed citations
2.
Quillien, Véronique, Céline Callens, François‐Clément Bidard, et al.. (2023). Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients. Clinica Chimica Acta. 545. 117366–117366. 4 indexed citations
3.
Lehmann‐Che, Jacqueline, Ludovic Lacroix, Magali Lacroix‐Triki, et al.. (2021). 159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers. Annals of Oncology. 32. S430–S430.
4.
Lacroix‐Triki, Magali, Laurent Arnould, Gaëtan MacGrogan, et al.. (2019). Abstract P4-08-23: EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures. Cancer Research. 79(4_Supplement). P4–8.
5.
Avril, Tony, Amandine Etcheverry, Raphaël Pineau, et al.. (2017). CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma. Clinical Cancer Research. 23(23). 7360–7374. 34 indexed citations
6.
Obacz, Joanna, Tony Avril, Pierre‐Jean Le Reste, et al.. (2017). Endoplasmic reticulum proteostasis in glioblastoma—From molecular mechanisms to therapeutic perspectives. Science Signaling. 10(470). 102 indexed citations
7.
Quillien, Véronique, Audrey Lavenu, François Ducray, et al.. (2017). Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. Cancer Biomarkers. 20(4). 435–441. 14 indexed citations
8.
Reste, Pierre‐Jean Le, Tony Avril, Véronique Quillien, Xavier Morandi, & Éric Chevet. (2016). Signaling the Unfolded Protein Response in primary brain cancers. Brain Research. 1642. 59–69. 16 indexed citations
9.
Etcheverry, Amandine, Marc Aubry, Ahmed Idbaïh, et al.. (2014). DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide. PLoS ONE. 9(9). e104455–e104455. 19 indexed citations
10.
11.
Vauléon, Élodie, Tony Avril, Abderrahmane Hamlat, et al.. (2012). Immune genes are associated with human glioblastoma pathology and patient survival. BMC Medical Genomics. 5(1). 41–41. 42 indexed citations
12.
Péré, Hélène, Corinne Tanchot, Jagadeesh Bayry, et al.. (2012). Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. OncoImmunology. 1(3). 326–333. 87 indexed citations
13.
14.
Tayrac, Marie de, Marc Aubry, Stéphan Saïkali, et al.. (2011). A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas. Clinical Cancer Research. 17(2). 317–327. 62 indexed citations
15.
Collet, Brigitte, Nathalie Guitton, Stéphan Saïkali, et al.. (2011). Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Science. 9(1). 16–16. 38 indexed citations
16.
Etcheverry, Amandine, Marc Aubry, Marie de Tayrac, et al.. (2010). DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics. 11(1). 701–701. 179 indexed citations
17.
Tayrac, Marie de, Amandine Etcheverry, Marc Aubry, et al.. (2008). Integrative genome‐wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes and Cancer. 48(1). 55–68. 72 indexed citations
18.
Quillien, Véronique, Thierry Lesimple, & Louis Toujas. (2003). Thérapies cellulaires vaccinales dans le mélanome. Bulletin du Cancer. 90(8). 722–733. 2 indexed citations
19.
Eche, N., M. Pichon, Véronique Quillien, et al.. (2001). [Standards, options and recommendations for tumor markers in colorectal cancer].. PubMed. 88(12). 1177–206. 14 indexed citations
20.
Quillien, Véronique, et al.. (1996). Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients.. PubMed. 15(6B). 2857–63. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deric M. Park Breakdown of academic impact, for papers by Yu Yao Breakdown of academic impact, for papers by Karim Y. Helmy Breakdown of academic impact, for papers by Ken Aldape Breakdown of academic impact, for papers by Gouri J. Nanjangud Breakdown of academic impact, for papers by Martha Chekenya Breakdown of academic impact, for papers by Serena Pellegatta Breakdown of academic impact, for papers by Chunhui Di Breakdown of academic impact, for papers by Olga A. Guryanova Breakdown of academic impact, for papers by Alexander Schulte
Rankless by CCL
2026